Currently, the most successful way of interfering with the GH–GHR interaction is an hGHR antagonist, Somavert (pegvisomant for injection; Pfizer Inc), which was discovered in our laboratory in the early 1990s and is currently an Food and Drug Administration (FDA)-approved treatment for patients with acromegaly (16). Here, GH1 is linked to acromegaly.